$ALDX
Aldeyra Therapeutics, Inc.

2018 Q1 Form 10-K Financial Statement

#000119312518102077 Filed on March 29, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.890M $6.190M $1.210M
YoY Change 9.25% 12.14% -1.63%
% of Gross Profit
Research & Development $6.600M $16.30M $3.450M
YoY Change 95.91% 23.73% 10.93%
% of Gross Profit
Depreciation & Amortization $11.41K $37.85K $10.00K
YoY Change 18.07% 5.75% 0.0%
% of Gross Profit
Operating Expenses $6.600M $16.30M $4.650M
YoY Change 95.91% 23.73% 7.14%
Operating Profit -$8.491M -$22.49M
YoY Change 66.63% 20.28%
Interest Expense $28.04K $113.5K $0.00
YoY Change 4.5% 7.53% -100.0%
% of Operating Profit
Other Income/Expense, Net $94.35K $147.8K
YoY Change 1873.77% -4356.88%
Pretax Income -$8.397M -$22.34M -$4.650M
YoY Change 64.97% 19.47% 6.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.397M -$22.34M -$4.650M
YoY Change 64.94% 19.47% 6.65%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$433.7K -$1.403M -$369.6K
COMMON SHARES
Basic Shares Outstanding 19.66M shares 12.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.90M $42.95M $24.90M
YoY Change 24.68% 72.42% -9.78%
Cash & Equivalents $20.96M $20.02M $12.02M
Short-Term Investments $18.00M $22.92M $12.90M
Other Short-Term Assets $1.700M $1.020M $200.0K
YoY Change 466.67% 363.64% -60.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.61M $43.97M $25.13M
YoY Change 29.01% 74.97% -10.53%
LONG-TERM ASSETS
Property, Plant & Equipment $170.9K $40.00K $56.35K
YoY Change 193.15% -33.33% -29.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $170.0K $0.00
YoY Change
Total Long-Term Assets $170.9K $200.0K $56.35K
YoY Change 193.15% 233.33% -51.66%
TOTAL ASSETS
Total Short-Term Assets $40.61M $43.97M $25.13M
Total Long-Term Assets $170.9K $200.0K $56.35K
Total Assets $40.78M $44.17M $25.19M
YoY Change 29.32% 75.35% -10.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.619M $1.000M $275.4K
YoY Change 132.96% 257.14% -67.64%
Accrued Expenses $1.815M $2.240M $1.946M
YoY Change 19.41% 14.87% 64.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $232.6K $120.0K $77.55K
YoY Change 20.0% 50.0% 0.0%
Total Short-Term Liabilities $3.667M $3.350M $2.299M
YoY Change 52.21% 45.65% 8.7%
LONG-TERM LIABILITIES
Long-Term Debt $1.108M $1.220M $1.239M
YoY Change -1.75% -1.61% 2.25%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.108M $1.220M $1.239M
YoY Change -1.75% -1.61% 2.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.667M $3.350M $2.299M
Total Long-Term Liabilities $1.108M $1.220M $1.239M
Total Liabilities $4.775M $4.570M $3.538M
YoY Change 35.01% 29.1% 6.36%
SHAREHOLDERS EQUITY
Retained Earnings -$108.0M -$77.30M
YoY Change 31.13% 31.91%
Common Stock $144.1M $98.95M
YoY Change 30.5% 18.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $36.00M $39.60M $21.65M
YoY Change
Total Liabilities & Shareholders Equity $40.78M $44.17M $25.19M
YoY Change 29.32% 75.35% -10.7%

Cashflow Statement

Concept 2018 Q1 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$8.397M -$22.34M -$4.650M
YoY Change 64.94% 19.47% 6.65%
Depreciation, Depletion And Amortization $11.41K $37.85K $10.00K
YoY Change 18.07% 5.75% 0.0%
Cash From Operating Activities -$7.955M -$19.22M -$3.910M
YoY Change 89.85% 26.88% 31.21%
INVESTING ACTIVITIES
Capital Expenditures $139.0K $24.76K $0.00
YoY Change 1099.15% 109.64%
Acquisitions
YoY Change
Other Investing Activities $4.940M -$10.17M $1.320M
YoY Change 448.89% 4742.86% -110.19%
Cash From Investing Activities $4.801M -$10.20M $1.320M
YoY Change 439.49% 4333.84% -110.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.093M $37.47M
YoY Change -61.32% 196.21%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.093M 37.43M 40.00K
YoY Change -61.31% 193.79% -200.0%
NET CHANGE
Cash From Operating Activities -7.955M -19.22M -3.910M
Cash From Investing Activities 4.801M -10.20M 1.320M
Cash From Financing Activities 4.093M 37.43M 40.00K
Net Change In Cash 940.2K 8.008M -2.550M
YoY Change -87.09% -403.34% -84.03%
FREE CASH FLOW
Cash From Operating Activities -$7.955M -$19.22M -$3.910M
Capital Expenditures $139.0K $24.76K $0.00
Free Cash Flow -$8.094M -$19.25M -$3.910M
YoY Change 92.63% 26.95% 31.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
178000
CY2012Q2 aldx Warrant Liability
WarrantLiability
88000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19664921 shares
CY2017Q2 dei Entity Public Float
EntityPublicFloat
60469344
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14648866
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
24878319
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1946251
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25131327
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
24517796
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
98938446
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
275441
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
129
CY2016Q4 us-gaap Assets
Assets
25187679
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
12897584
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12015061
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12576325 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12576325 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
12576
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
31292
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
700215
CY2016Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
77546
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1238624
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
218682
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56352
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-77301334
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1498585 shares
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21817769
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
31292
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
16669295
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
772841
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21786477
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
3861
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1271891
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2399666
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
983449
CY2016Q4 us-gaap Liabilities
Liabilities
3537862
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25187679
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2299238
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.63
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
21649817
CY2016Q4 aldx Deferred Tax Liabilities Note Discounts
DeferredTaxLiabilitiesNoteDiscounts
31292
CY2016Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
913838
CY2016Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
48964
CY2016Q4 aldx Class Of Warrant Or Right Issued And Expired
ClassOfWarrantOrRightIssuedAndExpired
0 shares
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2236465
CY2017Q4 us-gaap Assets Current
AssetsCurrent
43965766
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41967314
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
139241635
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1000963
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17831
CY2017Q4 us-gaap Assets
Assets
44174958
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2017Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
22923462
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
40941293
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20023337
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.87
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19137639 shares
CY2017Q4 us-gaap Cash
Cash
979485
CY2017Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.52
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1384608 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19137639 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
19138
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
16206
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
325744
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
22139498
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
16206
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
16935101
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
615490
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
22123292
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
6409
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2058771
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2197983
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
788570
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3700000
CY2017Q4 us-gaap Liabilities
Liabilities
4573939
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44174958
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3353747
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
0
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
1395833
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
116319
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
348958
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
465278
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
465278
CY2017Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
116319
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1220192
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1043852
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
237671
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
669263
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
228320
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
203272
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99641923
CY2017Q4 us-gaap Securities For Reverse Repurchase Agreements
SecuritiesForReverseRepurchaseAgreements
18000000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1018967
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43262
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3029015
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4683444
CY2017Q4 us-gaap Share Price
SharePrice
6.80
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1176178 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.46
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2246857 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
39601019
CY2017Q4 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
22941293
CY2017Q4 aldx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
165930
CY2017Q4 aldx Deferred Tax Liabilities Note Discounts
DeferredTaxLiabilitiesNoteDiscounts
16206
CY2017Q4 aldx Indemnification Obligations Claims Outstanding
IndemnificationObligationsClaimsOutstanding
0
CY2017Q4 aldx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1327103
CY2017Q4 aldx Accrued General And Administrative Expense Current
AccruedGeneralAndAdministrativeExpenseCurrent
120792
CY2017Q4 aldx Cash Reserve For Indemnities And Guarantees
CashReserveForIndemnitiesAndGuarantees
0
CY2017Q4 aldx Class Of Warrant Or Right Issued And Expired
ClassOfWarrantOrRightIssuedAndExpired
0 shares
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
27314
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2759753
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2910289 shares
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2759753
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-266106
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2633805
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18690960
CY2016 us-gaap Depreciation
Depreciation
35792
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3942 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0263 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0524 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0284 pure
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0003 pure
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5520308
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
759822
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-575719
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-278870
CY2016 us-gaap Interest Expense
InterestExpense
105509
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
102037
CY2016 us-gaap Interest Paid
InterestPaid
78128
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
123580
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-225234
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15147512
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12738941
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-18699450
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-18695978
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3472
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8490
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8490
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
16048424
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11810
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1189000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12649859
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
89082
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
15835000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13175670
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2759753
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.43
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12613623
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
89082
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11352230 shares
CY2016 aldx Class Of Warrants Or Right Exercised
ClassOfWarrantsOrRightExercised
0
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
20341
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2714841
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3788593 shares
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2714841
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-129245
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> <b><i>Concentration of Credit Risk</i></b> &#x2013; Financial instruments that potentially subject the Company to significant concentrations of credit risk principally consist of cash, cash equivalents and marketable securities. We place our cash and cash equivalents and marketable securities with financial institutions which management believes has high credit ratings. As part of our cash and investment management processes, we perform periodic evaluations of the credit standing of the financial institutions with whom we maintain deposits, and have not recorded any credit losses <font style="WHITE-SPACE: nowrap">to-date.</font></p> </div>
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8008276
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22358549
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 us-gaap Depreciation
Depreciation
37849
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M16D
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0151 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0111 pure
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0537 pure
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.0300 pure
CY2017 dei Entity Registrant Name
EntityRegistrantName
ALDEYRA THERAPEUTICS, INC.
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001341235
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.3975 pure
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
800285
CY2017 us-gaap Interest Expense
InterestExpense
113453
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.0000 pure
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6185820
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
290214
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
725522
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
261252
CY2017 us-gaap Interest Paid
InterestPaid
91633
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
157682
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="PAGE-BREAK-INSIDE: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra) was incorporated in the state of Delaware on August&#xA0;13, 2004 as Neuron Systems, Inc. On December&#xA0;20, 2012, the Company changed its name to Aldexa Therapeutics, Inc. and, on March&#xA0;17, 2014, the Company changed its name to Aldeyra Therapeutics, Inc. Aldeyra is developing next-generation medicines to improve the lives of patients with inflammatory diseases.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s principal activities to date include raising capital and research and development activities.</p> </div>
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10197842
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19222862
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
37428980
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-22340589
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-22488388
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
147799
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17960
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17960
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
35095083
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24759
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2784000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37469611
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
125299
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24922000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16302568
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2714841
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M22D
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M25D
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
151065 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15921884 shares
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
300000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> <b><i>Use of Estimates</i></b> &#x2013; The preparation of financial statements in conformity with US&#xA0;GAAP requires management to make estimates and assumptions, including fair value estimates for investments that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s financial statements relate to accruals, including research and development costs, accounting for income taxes and the related valuation allowance and accounting for stock based compensation and the related fair value. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p> </div>
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.76
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.02
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.13
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
899337 shares
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
125292
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37469611
CY2017 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
7
CY2017 dei Trading Symbol
TradingSymbol
ALDX
CY2017 aldx Class Of Warrants Or Right Exercised
ClassOfWarrantsOrRightExercised
0
CY2017 aldx Investment Maturity Period
InvestmentMaturityPeriod
Three months or less
CY2017 aldx Net Operating Loss Carry Forwards Expiration Year
NetOperatingLossCarryForwardsExpirationYear
2037
CY2017 aldx Deferred Tax Assets Tax Credit Carryforwards Research Expiration Year
DeferredTaxAssetsTaxCreditCarryforwardsResearchExpirationYear
2037
CY2017 aldx Number Of Incentive Plans
NumberOfIncentivePlans
3 Incentive_Plan
CY2017 aldx Investment Securities Maturity Period
InvestmentSecuritiesMaturityPeriod
P90D
CY2017 aldx Class Of Warrant Or Right Weighted Average Remaining Life Of Warrant Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingLifeOfWarrantOrRights
P1M6D
CY2017 aldx Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2017 aldx Deferred Offering Costs Paid In Cash
DeferredOfferingCostsPaidInCash
165930
CY2017 aldx Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Assets Decrease In Valuation Allowance
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetsDecreaseInValuationAllowance
8900000
CY2017 aldx Tax Cuts And Jobs Act Of2017 Change In Tax Rate Decrease In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateDecreaseInDeferredTaxAssets
8900000

Files In Submission

Name View Source Status
0001193125-18-102077-index-headers.html Edgar Link pending
0001193125-18-102077-index.html Edgar Link pending
0001193125-18-102077.txt Edgar Link pending
0001193125-18-102077-xbrl.zip Edgar Link pending
aldx-20171231.xml Edgar Link completed
aldx-20171231.xsd Edgar Link pending
aldx-20171231_cal.xml Edgar Link unprocessable
aldx-20171231_def.xml Edgar Link unprocessable
aldx-20171231_lab.xml Edgar Link unprocessable
aldx-20171231_pre.xml Edgar Link unprocessable
d519779d10k.htm Edgar Link pending
d519779dex1028.htm Edgar Link pending
d519779dex231.htm Edgar Link pending
d519779dex311.htm Edgar Link pending
d519779dex312.htm Edgar Link pending
d519779dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g519779g0321134308341.jpg Edgar Link pending
g519779g0321134308575.jpg Edgar Link pending
g519779g11x36.jpg Edgar Link pending
g519779g52z06.jpg Edgar Link pending
g519779g53c85.jpg Edgar Link pending
g519779g66n80.jpg Edgar Link pending
g519779g70y00.jpg Edgar Link pending
g519779g71k01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending